PIK3CA mutations are frequently associated with breast cancer with a prevalence of around 40%. These are somatic mutations that code for PI3 kinases, and this, along with Akt and mTOR signaling ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

Red bars indicate co-occurring mutations. EGFR_ECD, extracellular domain mutations of EGFR; EGFR_KD, kinase domain mutations of EGFR; PIK3CA_KD, kinase domain mutation of PIK3CA; PIK3CA_HD ...

Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...